{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:01:52Z","timestamp":1787317312462,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,26]],"date-time":"2014-11-26T00:00:00Z","timestamp":1416960000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s40263-014-0216-9","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T13:53:32Z","timestamp":1417442012000},"page":"41-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Post-Injection Delirium\/Sedation Syndrome in Patients Treated with Olanzapine Pamoate: Mechanism, Incidence, and Management"],"prefix":"10.1007","volume":"29","author":[{"given":"Daniel","family":"Luedecke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sch\u00f6ttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Karow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Naber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,26]]},"reference":[{"key":"216_CR1","doi-asserted-by":"crossref","unstructured":"Abott C, Keith S. Antipsychotic treatment and adherence in schizophrenia. In: Haddad P, Lambert T, Lauriello J, editors. Antipsychotic long-acting injections. Oxford: Oxford University Press; 2011.","DOI":"10.1093\/med\/9780199586042.003.0001"},{"issue":"5","key":"216_CR2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00003495-199447050-00004","volume":"47","author":"JM Davis","year":"1994","unstructured":"Davis JM, et al. Depot antipsychotic drugs: place in therapy. Drugs. 1994;47(5):741\u201373.","journal-title":"Drugs"},{"issue":"5 Suppl","key":"216_CR3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881105057347","volume":"19","author":"S Dursun","year":"2005","unstructured":"Dursun S. An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia. J Psychopharmacol. 2005;19(5 Suppl):3\u20134.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"216_CR4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2850.2004.00826.x","volume":"12","author":"MX Patel","year":"2005","unstructured":"Patel MX, De Zoysa N, Baker D, et al. Antipsychotic depot medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs. 2005;12(2):237\u201344.","journal-title":"J Psychiatr Ment Health Nurs"},{"issue":"1","key":"216_CR5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0924-977X(97)00045-X","volume":"8","author":"JM Kane","year":"1998","unstructured":"Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol. 1998;8(1):55\u201366.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1\u20133","key":"216_CR6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","volume":"127","author":"C Leucht","year":"2011","unstructured":"Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia\u2013a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1\u20133):83\u201392.","journal-title":"Schizophr Res"},{"issue":"5","key":"216_CR7","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/schbul\/sbm137","volume":"34","author":"JC West","year":"2008","unstructured":"West JC, Marcus SC, Wilk J, et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull. 2008;34(5):995\u20131001.","journal-title":"Schizophr Bull"},{"issue":"1","key":"216_CR8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2011.143","volume":"18","author":"T Kishimoto","year":"2013","unstructured":"Kishimoto T, Agarwal V, Kishi T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013;18(1):53\u201366.","journal-title":"Mol Psychiatry"},{"issue":"8","key":"216_CR9","first-page":"649","volume":"23","author":"D Naber","year":"2009","unstructured":"Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009;23(8):649\u201359.","journal-title":"CNS Drugs"},{"key":"216_CR10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2147\/NDT.S5463","volume":"6","author":"R Lorenzo Di","year":"2010","unstructured":"Di Lorenzo R, Brogli A. Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsychiatr Dis Treat. 2010;6:573\u201381.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"17","key":"216_CR11","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2165\/11204930-000000000-00000","volume":"70","author":"JE Frampton","year":"2010","unstructured":"Frampton JE. Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia. Drugs. 2010;70(17):2289\u2013313.","journal-title":"Drugs"},{"key":"216_CR12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/NDT.S3072","volume":"6","author":"JP Lindenmayer","year":"2010","unstructured":"Lindenmayer JP. Long-acting injectable antipsychotics: focus on olanzapine pamoate. Neuropsychiatr Dis Treat. 2010;6:261\u20137.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"216_CR13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1517\/14656566.2011.553193","volume":"12","author":"D Naber","year":"2011","unstructured":"Naber D. Olanzapine pamoate for the treatment of schizophrenia. Expert Opin Pharmacother. 2011;12(4):627\u201333.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"216_CR14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4088\/JCP.11m07530","volume":"73","author":"JM Kane","year":"2012","unstructured":"Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(5):617\u201324.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"216_CR15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.schres.2013.06.041","volume":"150","author":"S Mallikaarjun","year":"2013","unstructured":"Mallikaarjun S, Kane JM, Bricmont P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 2013;150(1):281\u20138.","journal-title":"Schizophr Res"},{"issue":"5","key":"216_CR16","doi-asserted-by":"crossref","first-page":"790","DOI":"10.4088\/JCP.v69n0512","volume":"69","author":"J Lauriello","year":"2008","unstructured":"Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69(5):790\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"216_CR17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1176\/appi.ajp.2009.07081221","volume":"167","author":"JM Kane","year":"2010","unstructured":"Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167(2):181\u20139.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"216_CR18","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40263-013-0083-9","volume":"27","author":"AS Rauch","year":"2013","unstructured":"Rauch AS, Fleischhacker WW. Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs. 2013;27(8):637\u201352.","journal-title":"CNS Drugs"},{"key":"216_CR19","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.2147\/NDT.S50635","volume":"9","author":"A Ciudad","year":"2013","unstructured":"Ciudad A, Anand E, Casillas M, et al. Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses. Neuropsychiatr Dis Treat. 2013;9:1737\u201350.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"216_CR20","doi-asserted-by":"crossref","unstructured":"Detke HC, Weiden PJ, Llorca PM, et al. Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia. J Clin Psychopharmacol. 2014;34:426\u201334.","DOI":"10.1097\/JCP.0000000000000140"},{"key":"216_CR21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-244X-10-43","volume":"10","author":"HC Detke","year":"2010","unstructured":"Detke HC, McDonnell DP, Brunner E, et al. Post-injection delirium\/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry. 2010;10:43.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"216_CR22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2174\/157488611794480070","volume":"6","author":"L Alphs","year":"2011","unstructured":"Alphs L, Gopal S, Karcher K, et al. Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium\/sedation syndrome? An assessment of safety databases. Curr Drug Saf. 2011;6(1):43\u20135.","journal-title":"Curr Drug Saf"},{"issue":"2","key":"216_CR23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/WNF.0b013e3182854f70","volume":"36","author":"V Novakovic","year":"2013","unstructured":"Novakovic V, Adel T, Peselow E, et al. Long-acting injectable antipsychotics and the development of postinjection delirium\/sedation syndrome (PDSS). Clin Neuropharmacol. 2013;36(2):59\u201362.","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"216_CR24","first-page":"60","volume":"41","author":"SF Duran-Sindreu","year":"2013","unstructured":"Duran-Sindreu SF, Grasa-Bello E, Corripio-Collado I, et al. Olanzapine long-acting post-injection syndrome: a case report and brief review [in Spanish]. Actas Esp Psiquiatr. 2013;41(1):60\u20132.","journal-title":"Actas Esp Psiquiatr"},{"key":"216_CR25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4137\/CMPsy.S6659","volume":"3","author":"DP McDonnell","year":"2011","unstructured":"McDonnell DP, Andersen SW, Detke HC, et al. Long-term safety and tolerability of open-label olanzapine long-acting injection in the treatment of schizophrenia: 190-week interim results. Clin Med Insights Psychiatry. 2011;3:37\u201347.","journal-title":"Clin Med Insights Psychiatry"},{"key":"216_CR26","unstructured":"Eli Lilly and Company. Olanzapine pamoate depot versus oral olanzapine on treatment outcomes in outpatients with schizophrenia [ClinicalTrials.gov identifier NCT00320489]. US National Institutes of Health, ClinicalTrials.gov. http:\/\/www.clinicaltrials.gov . Accessed 30 Mar 2013."},{"key":"216_CR27","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2147\/IJGM.S29052","volume":"5","author":"H Ascher-Svanum","year":"2012","unstructured":"Ascher-Svanum H, Montgomery WS, McDonnell DP, et al. Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons. Int J Gen Med. 2012;5:391\u20138.","journal-title":"Int J Gen Med"},{"issue":"2","key":"216_CR28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.npp.1301409","volume":"33","author":"D Mamo","year":"2008","unstructured":"Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology. 2008;33(2):298\u2013304.","journal-title":"Neuropsychopharmacology"},{"key":"216_CR29","unstructured":"FDA Drug Safety Communication. FDA is investigating two deaths following injection of long-acting antipsychotic Zyprexa Relprevv (olanzapine pamoate). 2013. Available at http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm356971.htm . Accessed 20 June 2013"},{"issue":"1\u20133","key":"216_CR30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.forsciint.2012.05.028","volume":"222","author":"E Saar","year":"2012","unstructured":"Saar E, Beyer J, Gerostamoulos D, et al. The time-dependant post-mortem redistribution of antipsychotic drugs. Forensic Sci Int. 2012;222(1\u20133):223\u20137.","journal-title":"Forensic Sci Int"},{"key":"216_CR31","unstructured":"Kurtz D, Bergstrom R, McDonnell D, et al. Pharmacokinetics (PK) of multiple doses of olanzapine long-acting injection (OLAI), an intramuscular (IM) depot formulation of olanzapine (OLZ), in stabilized patients with schizophrenia. Biol Psychiatry. 2008; 63(Suppl. 1):228\u2013235."},{"key":"216_CR32","unstructured":"Eli Lilly and Company. FDA issues not-approvable letter for Lilly\u2019s Zyprexa\u00ae long-acting injection (LAI) for schizophrenia treatment. 28 February 2008. http:\/\/newsroom.lilly.com\/ReleaseDetail.cfm?ReleaseID=296550 . Accessed Aug 2008."},{"key":"216_CR33","unstructured":"Zyprexa\u00ae Relprevv\u2122. Full prescribing information. Indianapolis: Lilly USA, LLC; 2011 Jul 5."},{"key":"216_CR34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-244X-10-45","volume":"10","author":"DP McDonnell","year":"2010","unstructured":"McDonnell DP, Detke HC, Bergstrom RF, et al. Post-injection delirium\/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry. 2010;10:45.","journal-title":"BMC Psychiatry."},{"issue":"Suppl. 1","key":"216_CR35","first-page":"152","volume":"11","author":"A Gulliver","year":"2008","unstructured":"Gulliver A, McDonnell DP, Sorsaburu S, et al. Injection-related adverse events observed with olanzapine long-acting injection [abstract]. Int J Neuropsychopharmacol. 2008;11(Suppl. 1):152.","journal-title":"Int J Neuropsychopharmacol."},{"issue":"1","key":"216_CR36","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1742-1241.2008.01900.x","volume":"63","author":"L Citrome","year":"2009","unstructured":"Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract. 2009;63(1):140\u201350.","journal-title":"Int J Clin Pract"},{"key":"216_CR37","unstructured":"EMA. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000890\/WC500054429.pdf . Accessed 30 Mar 2014."},{"issue":"1","key":"216_CR38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/schbul\/sbs150","volume":"40","author":"T Kishimoto","year":"2014","unstructured":"Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192\u2013213.","journal-title":"Schizophr Bull"},{"issue":"6","key":"216_CR39","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1517\/14740338.2013.832753","volume":"12","author":"D Schottle","year":"2013","unstructured":"Schottle D, Kuhnigk O, Naber D. Drug safety evaluation of olanzapine pamoate. Expert Opin Drug Saf. 2013;12(6):897\u2013903.","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"216_CR40","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMoa1005987","volume":"364","author":"RA Rosenheck","year":"2011","unstructured":"Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842\u201351.","journal-title":"N Engl J Med"},{"issue":"11","key":"216_CR41","first-page":"23","volume":"7","author":"W Macfadden","year":"2010","unstructured":"Macfadden W, Ma YW, Haskins JT, et al. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry (Edgmont). 2010;7(11):23\u201331.","journal-title":"Psychiatry (Edgmont)"},{"issue":"6","key":"216_CR42","doi-asserted-by":"crossref","first-page":"568","DOI":"10.4088\/JCP.12r08167","volume":"74","author":"NY Kirson","year":"2013","unstructured":"Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74(6):568\u201375.","journal-title":"J Clin Psychiatry"},{"key":"216_CR43","unstructured":"European Medicines Agency. Zypadhera: procedural steps taken and scientific information after the authorisation. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation\/human\/000890\/WC500089567.pdf . Accessed 30 Mar 2014."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0216-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-014-0216-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0216-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T21:02:39Z","timestamp":1566075759000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-014-0216-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,26]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["216"],"URL":"https:\/\/doi.org\/10.1007\/s40263-014-0216-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,26]]}}}